The present invention relates to an insulin resistance evaluation supporting system that supports evaluation of the insulin resistance of a subject, a method thereof, and a computer program product for the insulin resistance evaluation supporting system.
Insulin resistance is one of the disease states of diabetes, and is known as an important background factor of metabolic syndrome. Conventionally, a glucose clamp test is used for evaluating insulin resistance. The glucose clamp test is a test that injects insulin to a vein of a subject using an artificial pancreas, and regulates the injecting rate of glucose so as to keep the blood glucose level constant. This test method is highly invasive to a subject and places a heavy burden on the subject.
Japanese Laid-Open Patent Publication No. 2006-304833 discloses a diagnosis supporting system that receives “fasting insulin level”, “blood glucose level at 2 hours after meal”, “HOMA-IR”, and “insulin OGTT peak level” as input values, performs a peripheral insulin resistance determining process for obtaining scores by comparing these respective input values with pre-set determination reference values, and thus analyzes the risk of contracting diabetes and metabolic syndrome.
However, the diagnosis supporting system described in Japanese Laid-Open Patent Publication No. 2006-304833 requires test results of an oral glucose tolerance test (OGTT: Oral Glucose Tolerance Test) as input information. The OGTT is a test that causes a subject to orally ingest dextrose, and collects blood several times after a predetermined period to measure the blood glucose level and the blood insulin concentration, that is, the burden of this test on a subject is lighter than that of glucose clamp, but the test takes several hours.
An aspect of the present invention is directed to an insulin resistance evaluation supporting system for supporting evaluation of insulin resistance of a subject, comprising: an input section that receives input of information relating to a glucose concentration, an insulin concentration, and a free fatty acid concentration in blood obtained by measuring the subject; and an estimating section that estimates a glucose uptake rate of the subject based on the information relating to the glucose concentration, the insulin concentration, and the free fatty acid concentration in the blood whose input has been received by the input section.
Moreover, an aspect of the present invention is directed to an insulin resistance evaluation supporting method for supporting evaluation of insulin resistance of a subject using a computer provided with an input device, comprising the steps of: receiving from the input device, input of information relating to a glucose concentration, an insulin concentration, and a free fatty acid concentration in blood obtained by measuring the subject; and estimating, using the computer, a glucose uptake rate of the subject based on the information relating to the glucose concentration, the insulin concentration, and the free fatty acid concentration in the blood whose input has been received from the input device.
Moreover, an aspect of the present invention is directed to a computer program product for enabling a computer provided with an input device comprising: a computer readable medium, and software instructions, on the computer readable medium, for enabling the computer to perform predetermined operations comprising: receiving from the input device, input of information relating to a glucose concentration, an insulin concentration, and a free fatty acid concentration in blood obtained by measuring a subject; and estimating a glucose uptake rate of the subject based on the glucose concentration, the insulin concentration, and the free fatty acid concentration in the blood whose input has been received using the input device.
Hereinafter, preferred embodiments of the present invention will be described with reference to the drawings.
This embodiment relates to an insulin resistance evaluation supporting system that receives input of information relating to a glucose concentration, an insulin concentration, and a free fatty acid concentration in blood obtained by measuring a subject, and an amount of oxygen consumed and an amount of carbon dioxide produced per unit time in skeletal muscle, estimates a glucose uptake rate of the subject based on the information relating to the glucose concentration, the insulin concentration, and the free fatty acid concentration in the blood, and the amount of oxygen consumed and the amount of carbon dioxide produced per unit time in the skeletal muscle whose input has been received, estimates insulin resistance of the subject based on the estimated glucose uptake rate, and outputs a result of the estimation.
The CPU 11a can execute computer programs loaded into the RAM 11c. Execution of an insulin resistance evaluation supporting program 14a as described later by the CPU 11a allows the computer 1a to function as the insulin resistance evaluation supporting system 1.
The ROM 11b is configured from a mask ROM, a PROM, an EPROM, an EEPROM, or the like, and stores computer programs that are to be executed by the CPU 11a, data used for the execution, and the like.
The RAM 11c is configured from an SRAM, a DRAM, or the like. The RAM 11c is used to read the insulin resistance evaluation supporting program 14a stored in the hard disk 11d. Furthermore, the RAM 11c is used as a work area of the CPU 11a when the CPU 11a executes a computer program.
On the hard disk 11d, various computer programs (e.g., operating systems and application programs) that are to be executed by the CPU 11a and data used for the execution of the computer programs are installed. The insulin resistance evaluation supporting program 14a described later is also installed on the hard disk 11d.
The reading device 11e is configured from a flexible disk drive, a CD-ROM drive, a DVD-ROM drive, or the like, and can read computer programs or data stored in a portable storage medium 14. Furthermore, the portable storage medium 14 stores the insulin resistance evaluation supporting program 14a for causing a computer to function as an insulin resistance evaluation supporting system. The computer 1a can read the insulin resistance evaluation supporting program 14a from the portable storage medium 14, and install the insulin resistance evaluation supporting program 14a on the hard disk 11d.
Here, the insulin resistance evaluation supporting program 14a does not necessarily have to be provided by the portable storage medium 14, and can be provided through an electric telecommunication line (it may be either wired or wireless) from an external apparatus communicably connected via the electric telecommunication line to the computer 1a. For example, it is possible that the insulin resistance evaluation supporting program 14a is stored in a hard disk of a server computer on the Internet, and the computer 1a accesses the server computer to download and install the computer program on the hard disk 11d.
Furthermore, on the hard disk 11d, for example, a multi-task operating system such as Windows (registered trademark) manufactured and marketed by Microsoft Corporation (U.S.) is installed. In the following description, it is assumed that the insulin resistance evaluation supporting program 14a according to this embodiment operates on the operating system. The configuration of the insulin resistance evaluation supporting program 14a will be described later in detail.
The input/output interface 11f is configured from, for example, a serial interface such as a USB, an IEEE 1394, or an RS-232C, a parallel interface such as an SCSI, an IDE, or an IEEE 1284, an analog interface such as a D/A converter or an A/D converter. The input/output interface 11f is connected to the input portion 13 including a keyboard and a mouse, and a user can input data to the computer 1a using the input portion 13.
The image output interface 11g is connected to the image display portion 12 configured from an LCD, a CRT, or the like, and outputs video signals according to image data given from the CPU 11a to the image display portion 12. The image display portion 12 displays images (screens) according to the input video signals.
Next, the insulin resistance evaluation supporting program 14a will be described in more detail.
Hereinafter, the configuration of each block will be described in detail, but, prior to this description, the concept of an ordinary metabolism rate functioning as the basis of the calculation in each block will be described. An ordinarily irreversible enzyme reaction in a living organ is represented by the following formula.
X+Y+E1→V+W+E2 (1)
In the formula, X and Y refer to the concentrations of substrates metabolized, V and W refer to the concentrations of substrates produced, and E1 and E2 refer to ATP and ADP, or ADP and ATP, and/or NADH and NAD, or NAD and NADH.
The enzyme reaction represented by Formula (1) can also be represented by Formula (2) below.
The reaction rate fX+Y→V+W in the above-described enzyme reaction can be obtained by Formula (3) below.
In the formula, VX+Y→V+W refers to the maximum saturation rate, CX and CY refer to the concentrations of the substrates X and Y, PS+ refers to ATP/ADP, PS− refers to ADP/ATP, RS+ refers to NADH/NAD, RS− refers to NAD/NADH, and KX, KY, μ+, and ν+ refer to a Michaelis-Menten constant or a model parameter relating to metabolic control in the reaction process.
Here, it is assumed that the reaction rate, the production rate, and the concentration of a substance in the following description of the blocks 21 to 24 and the supplemental calculation process are the reaction rate (mmol/kg/min), the production rate (mmol/kg/min), and the concentration (mM) per unit weight, respectively, unless otherwise indicated.
The fatty acid metabolism block 21 is a functional block virtually reproducing a function of metabolizing fatty acid in a living organ. The fatty acid metabolism function of the body causes blood free fatty acid (FFA) to be taken up into the cell, produces triglyceride (TG) via diacylglycerol (DAG), and produces a fatty acyl-coenzyme A complex (FAC) from the free fatty acid. The fatty acid metabolism block 21 represents such a fatty acid metabolism function of the body. Execution of the fatty acid metabolism block 21 by the CPU 11a allows the reaction rate fFFA→TG of converting free fatty acid into triglyceride, the reaction rate fFFA→FAC of producing a fatty acyl-coenzyme A complex from free fatty acid, and the reaction rate fTG→FFA of producing free fatty acid from triglyceride to be calculated based on the intracellular free fatty acid concentration, and the intracellular free fatty acid concentration, triglyceride concentration, and fatty acyl-coenzyme A complex concentration after a specific period of time to be calculated.
Hereinafter, a chemical reaction relating to the fatty acid metabolism function of the living organ and a specific calculation process of the fatty acid metabolism block 21 based thereon will be described. Here, the intracellular concentrations of free fatty acid, triglyceride, ATP, ADP, a fatty acyl-coenzyme A complex, and phosphoric acid in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations. First, blood free fatty acid is taken up into a cell, and the passive inflow rate fFFA of free fatty acid from blood into a tissue (cell) at that time is represented by Formula (4) below.
In the formula, fO2 refers to the rate of oxygen consumed in a tissue, and is obtained from the amount of oxygen consumed per unit time in the skeletal muscle and the skeletal muscle percentage that have been input. Furthermore, fCO2 refers to the rate of carbon dioxide produced in the tissue, and is obtained from the amount of carbon dioxide produced per unit time in the skeletal muscle and the skeletal muscle percentage that have been input.
The above-described inflow rate (rate of uptake into a tissue) fFFA of free fatty acid can also be represented by Formula (5) below.
f
FFA=λFFA(CFFAb+σFFA·CFFA) (5)
In the formula, CFFAb refers to the blood free fatty acid concentration, CFFA refers to the intracellular free fatty acid concentration, λFFA refers to a membrane transport coefficient of FFA having membrane permeability, and σFFA refers to a distribution coefficient relating to FFA. If the CPU 11a applies fFFA obtained by Formula (4) and the input blood free fatty acid concentration to Formula (5), the intracellular free fatty acid concentration FFA is calculated.
Next, the free fatty acid (FFA) taken up into the cell is converted via diacylglycerol to triglyceride (TG).
3FFA+6ATP→TG+6ADP (6)
The rate of this reaction is represented by Formula (7) below.
Furthermore, a fatty acyl-coenzyme A complex (FAC) is produced from free fatty acid (FFA) and coenzyme A (CoA).
FFA+CoA+2ATP→FAC+2ADP+2Pi (8)
The rate of this reaction is represented by Formula (9) below.
Moreover, triglyceride decomposes to give free fatty acid as shown in Formula (10) below.
TG→3FFA (10)
The rate of this reaction is represented by Formula (11) below.
The fatty acyl-coenzyme A complex produced by the reaction of Formula (8) above is given to mitochondria. Furthermore, the concentration information of the fatty acyl-coenzyme A complex is updated as below.
In the fatty acid metabolism block 21, the CPU 11a calculates the reaction rates fFFA→TG, fFFA→FAC, and fTG→FFA represented by Formulae (7), (9), and (11) above, respectively.
Furthermore, in the fatty acid metabolism block 21, the CPU 11a calculates the production rate of free fatty acid represented by Formula (12) below, the production rate of triglyceride represented by Formula (13) below, and the production rate of fatty acyl-coenzyme A complex represented by Formula (14) below.
In Formula (12), the reaction rate fFAC→ACoA is represented by Formula (30) described later, and calculated in the mitochondria block 24. If no calculation has been performed in the mitochondria block 24, the initial value of the reaction rate fFAC→ACoA is used.
Furthermore, in the fatty acid metabolism block 21, the CPU 11a calculates the amounts of free fatty acid, triglyceride, and fatty acyl-coenzyme A complex produced in a specific period of time respectively from the thus obtained rates of free fatty acid, triglyceride, and fatty acyl-coenzyme A complex produced, and reflects these amounts on the free fatty acid concentration, the triglyceride concentration, and the fatty acyl-coenzyme A complex concentration at that time, thereby calculating the intracellular free fatty acid concentration, triglyceride concentration, and fatty acyl-coenzyme A complex concentration after the specific period of time. Here, in this embodiment, the specific period of time is a constant, but this value may be set by the user.
Furthermore, as described later, the fatty acid metabolism block 21 is used both in a first glucose uptake rate estimating process and in a second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the fatty acid metabolism block 21 is used to perform a process that calculates the intracellular free fatty acid concentration, triglyceride concentration, and fatty acyl-coenzyme A complex concentration in a fasted state. Furthermore, in the second glucose uptake rate estimating process, the fatty acid metabolism block 21 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
The insulin signaling block 22 is a functional block virtually reproducing a function of adjusting the glucose transporter (GLUT4) appearance amount in a living organ. The function of adjusting the GLUT4 appearance amount in a living body adjusts the GLUT4 appearance amount according to the amount of insulin binding to insulin receptors and the concentrations of fatty acyl-coenzyme A complex and diacylglycerol formed as metabolites of the fatty acid metabolism. The insulin signaling block 22 according to this embodiment represents such a function of adjusting the GLUT4 appearance amount in the body. Execution of the insulin signaling block 22 by the CPU 11a allows a value according to the GLUT4 appearance amount to be calculated based on the plasma insulin concentration (PI) and the FAC concentration.
Hereinafter, a specific calculation process of the insulin signaling block 22 based on the function of adjusting the GLUT4 appearance amount in the living organ will be described. The function of adjusting the GLUT4 appearance amount in the living organ is characterized in that, as the plasma insulin concentration is increased, the GLUT4 appearance amount is increased, and, as the FAC concentration and the DAG concentration are increased, the GLUT4 appearance amount is suppressed. In consideration of these characteristics, in the insulin signaling block 22, a glucose uptake (GLUT), which is a value according to the GLUT4 appearance amount, is calculated following Formula (15) below using the input plasma insulin concentration and the FAC concentration obtained through the calculation in the fatty acid metabolism block 21. Here, in this embodiment, the glucose uptake is calculated without consideration of the DAG concentration.
In the formula, Vmax refers to a predetermined coefficient, and nPI and nFAC refer to constants. Here, the glucose uptake GLUT is a real number proportional to the GLUT4 appearance amount.
Furthermore, as described later, the insulin signaling block 22 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the insulin signaling block 22 is used to perform a process that calculates the glucose uptake GLUT in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the insulin signaling block 22 is used to perform a process that calculates the glucose uptake GLUT in a hyperinsulinemic state.
The glycolysis block 23 is a functional block virtually reproducing a function of causing glucose to decompose in a living organ. The glucose decomposition function of the body causes glucose to be taken up into the cell according to the GLUT4 appearance amount and causes the glucose in the cell to decompose to give pyruvic acid via G6P (glucose 6-phosphate) and GA3P (glyceraldehyde 3-phosphate). The glycolysis block 23 represents such a glucose decomposition function of the body. Execution of the glycolysis block 23 by the CPU 11a allows the glucose uptake rate to be calculated based on the glucose uptake GLUT obtained in the insulin signaling block 22 and the rate of oxygen consumed and the rate of carbon dioxide produced in the tissue, and the reaction rate fGLU→G6P of converting glucose into G6P, the reaction rate fG6P→GA3P of converting G6P into GA3P, and the reaction rate fGA3P→PYR of converting GA3P into pyruvic acid to be calculated. Furthermore, the glucose concentration, the G6P concentration, the GA3P concentration, and the pyruvic acid concentration after a specific period of time are calculated based on these reaction rates.
Hereinafter, a chemical reaction relating to the glucose decomposition function of the living organ and a specific calculation process of the glycolysis block 23 based thereon will be described. Here, the intracellular concentrations of glucose, G6P, GA3P, pyruvic acid, NAD, and NADH in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations.
First, blood glucose is taken up into the cell according to the GLUT4 appearance amount (appearance amount on the cell surface). This uptake rate fGLU is represented by Formula (16) below.
f
GLU
=GLUT(CGLUb+σGLU·CGLU) (16)
In the formula, CGLUb refers to the input blood glucose concentration, CGLU refers to the intracellular glucose concentration, and σGLU refers to a distribution coefficient relating to glucose.
The glucose (GLU) taken up into the cell is phosphorylated to give G6P.
GLU+ATP→G6P+ADP (17)
The rate of this reaction is represented by Formula (18) below.
Furthermore, the G6P produced by the conversion reacts with ATP to give GA3P and ADP as shown in the following formula.
G6P+ATP→2GA3P+ADP (19)
The rate of this reaction is represented by Formula (20) below.
The GA3P produced by the conversion is converted to pyruvic acid (PYR) according to the following formula.
GA3P+Pi+NAD+2ADP→PYR+NADH+2ATP (21)
The reaction rate of the conversion to PYR is represented by Formula (22) below.
In the glycolysis block 23, the CPU 11a calculates the reaction rates fGLU→G6P, fG6P→GA3P, and fGA3P→PYR represented by Formulae (18), (20), and (22) above, respectively.
Furthermore, in the glycolysis block 23, the CPU 11a calculates the production rate of glucose represented by Formula (23) below, the production rate of G6P represented by Formula (24) below, the production rate of GA3P represented by Formula (25) below, and the production rate of pyruvic acid represented by Formula (26) below.
In Formula (26), the reaction rate fPYR→ACoA is represented by Formula (28) described later, and calculated in the mitochondria block 24. If no calculation has been performed in the mitochondria block 24, the initial value of the reaction rate fPYR→ACoA is used.
Furthermore, in the glycolysis block 23, the CPU 11a calculates the amounts of glucose, G6P, GA3P, and pyruvic acid produced in a specific period of time respectively from the thus obtained rates of glucose, G6P, GA3P, and pyruvic acid produced, and reflects these amounts on the intracellular glucose concentration, G6P concentration, GA3P concentration, and pyruvic acid concentration at that time, thereby calculating the intracellular glucose concentration, G6P concentration, GA3P concentration, and pyruvic acid concentration after the specific period of time.
Furthermore, as described later, the glycolysis block 23 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the glycolysis block 23 is used to perform a process that calculates the intracellular glucose concentration, G6P concentration, GA3P concentration, and pyruvic acid concentration in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the glycolysis block 23 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
The mitochondria block 24 is a functional block virtually reproducing a function of mitochondria in a living organ. The mitochondria produce acetyl coenzyme A (ACoA) by oxidizing the pyruvic acid and the fatty acyl-coenzyme A complex, and consume the acetyl coenzyme A in the TCA cycle. Fatty acid oxidization is suppressed according to the acetyl coenzyme A concentration. The mitochondria block 24 represents such a mitochondria function. Execution of the mitochondria block 24 by the CPU 11a allows the reaction rate fPYR→ACoA of producing acetyl coenzyme A from the pyruvic acid obtained in the glycolysis block 23, the reaction rate fFAC→ACoA of producing acetyl coenzyme A from the fatty acyl-coenzyme A complex obtained in the fatty acid metabolism block 21, the reaction rate fACoA→CO2 of producing carbon dioxide from the acetyl coenzyme A, and the reaction rate fO2→H2O of consuming oxygen and producing water to be calculated. Furthermore, the intracellular concentrations of acetyl coenzyme A, coenzyme A, oxygen, and carbon dioxide after a specific period of time are calculated based on these reaction rates.
Hereinafter, a chemical reaction relating to the mitochondria and a specific calculation process of the mitochondria block 24 based thereon will be described. Here, the intracellular concentrations of acetyl coenzyme A, coenzyme A, oxygen, and carbon dioxide in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations.
First, intracellular pyruvic acid is oxidized to give acetyl coenzyme A.
PYR+CoA+NAD→ACoA+NADH+CO2 (27)
The rate of this reaction is represented by Formula (28) below.
Furthermore, the fatty acyl-coenzyme A complex produced by the fatty acid metabolism function is oxidized to give acetyl coenzyme A as shown in Formula (29) below. This route is called β-oxidization.
The rate of this reaction is represented by Formula (30) below.
In the formula, CMCoA refers to the malonyl-CoA concentration, and is obtained by multiplying the ACoA concentration CACoA by a predetermined coefficient. In this manner, in the n-oxidization, the rate of acetyl coenzyme A produced is suppressed due to the malonyl-CoA concentration. Accordingly, the rate of acetyl-CoA produced in the β-oxidization is adjusted due to the malonyl-CoA concentration. Here, in the first calculation of Formula (30), a predetermined initial value of CMCoA is used, and, in the second and subsequent calculations, a value of CMCoA obtained through the calculation is used.
Furthermore, the fatty acyl-coenzyme A complex is metabolized in the TCA cycle, and ATP and NADH are newly produced.
ACoA+ADP+Pi+4NAD→2CO2+CoA+ATP+4NADH (31)
The rate of this reaction is represented by Formula (32) below.
Meanwhile, the relationship between the consumption of NADH, oxygen, and ADP and the synthesis of ATP in the mitochondria is represented by Formula (33) below.
O2+6ADP+6Pi+2NADH→2H2O+6ATP+2NAD (33)
The rate of this reaction is represented by Formula (34) below.
In the mitochondria block 24, the CPU 11a calculates the reaction rates fPYR→ACoA, fFAC→ACoA, fACoA→CO2, and fO2→H2O represented by Formulae (28), (30), (32), and (34) above, respectively.
As described above, the rate fO2 of oxygen consumed in the cell is determined by the amount of oxygen consumed per unit time in the skeletal muscle and the skeletal muscle percentage that have been input, but can also be represented by Formula (35) below.
f
O2=λO2(CO2b+σO2·CO2) (35)
In the formula, CO2b refers to the blood oxygen concentration (constant), CO2 refers to the intracellular oxygen concentration, λO2 refers to a membrane transport coefficient of oxygen having membrane permeability, and σO2 refers to a distribution coefficient relating to oxygen. The CPU 11a can obtain the intracellular oxygen concentration from Formula (35) above.
In a similar manner, as described above, the rate fCO2 of carbon dioxide produced in the cell is determined by the amount of carbon dioxide produced per unit time in the skeletal muscle and the skeletal muscle percentage that have been input, but can also be represented by the following formula.
f
CO2=λCO2(CCO2b+σCO2·CCO2) (36)
In the formula, CCO2b refers to the blood carbon dioxide concentration (constant), CCO2 refers to the intracellular carbon dioxide concentration, λCO2 refers to a membrane transport coefficient of carbon dioxide having membrane permeability, and σCO2 refers to a distribution coefficient relating to carbon dioxide. The CPU 11a obtains the intracellular carbon dioxide concentration from Formula (36) above.
Furthermore, in the mitochondria block 24, the CPU 11a calculates the production rate of acetyl coenzyme A represented by Formula (37) below and the production rate of coenzyme A represented by Formula (38) below.
Furthermore, in the mitochondria block 24, the CPU 11a calculates the amounts of oxygen, carbon dioxide, acetyl coenzyme A, and coenzyme A produced (consumed) in a specific period of time respectively from the thus obtained rates of oxygen, carbon dioxide, acetyl coenzyme A, and coenzyme A produced (consumed), and reflects these amounts on the free fatty acid concentration, the triglyceride concentration, and the fatty acyl-coenzyme A complex concentration at that time, thereby calculating the intracellular oxygen concentration, carbon dioxide concentration, acetyl coenzyme A concentration, and coenzyme A concentration after the specific period of time.
Furthermore, as described later, the mitochondria block 24 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the mitochondria block 24 is used to perform a process that calculates the intracellular oxygen concentration, carbon dioxide concentration, acetyl coenzyme A concentration, and coenzyme A concentration in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the mitochondria block 24 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
Furthermore, the CPU 11a performs a supplemental calculation process as described below.
When the ADP concentration is high, phosphocreatine (PCr) and ADP react with each other to give creatine (Cr) and ATP.
PCr+ADP→Cr+ATP (39)
The rate of this reaction is represented by Formula (40) below.
Meanwhile, as the ATP concentration is increased, creatine and ATP react with each other to give phosphocreatine and ADP.
Cr+ATP→PCr+ADP (41)
The rate of this reaction is represented by Formula (42) below.
Furthermore, ATP is hydrolyzed and converted to ADP according to the following formula.
ATP→ADP+Pi (43)
The rate of this reaction is represented by Formula (44) below.
In the supplemental calculation process, the CPU 11a calculates the reaction rates fPCr→Cr, fCr→PCr, and fATP→ADP represented by Formulae (40), (42), and (44) above, respectively.
Furthermore, the CPU 11a calculates the production rates of NAD, NADH, ATP, ADP, Pi, PCr, and Cr according to Formulae (45) to (51) below.
Furthermore, the CPU 11a calculates the amounts of NAD, NADH, ATP, ADP, Pi, PCr, and Cr produced in a specific period of time respectively from the thus obtained rates of NAD, NADH, ATP, ADP, Pi, PCr, and Cr produced, and reflects these amounts on the intracellular concentrations of NAD, NADH, ATP, ADP, Pi, PCr, and Cr at that time, thereby calculating the intracellular concentrations of NAD, NADH, ATP, ADP, Pi, PCr, and Cr after the specific period of time.
Furthermore, as described later, the supplemental calculation process is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the supplemental calculation process is executed to perform a process that calculates the intracellular concentrations of NAD, NADH, ATP, ADP, Pi, PCr, and Cr in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the supplemental calculation process is executed to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
Next, an operation of the insulin resistance evaluation supporting system 1 according to this embodiment will be described.
After the insulin resistance evaluation supporting program 14a is started, first, the CPU 11a displays an input screen for prompting the user to input the body weight, the amount of oxygen consumed, the amount of carbon dioxide produced, the skeletal muscle percentage, the blood glucose concentration, the plasma insulin concentration, and the blood free fatty acid concentration of the subject (step S1).
Once input of the biological information and the execution instruction is received from the user, the CPU 11a executes a first glucose uptake rate estimating process (step S3).
Next, the CPU 11a determines whether or not the fasting glucose uptake rate obtained in the above-described process reaches a steady state (step S308). In this embodiment, this process is performed by obtaining a difference between the glucose uptake rate obtained in the current calculation (turn) and the glucose uptake rate in the previous calculation (turn) stored in the RAM 11c, and determining whether or not the difference is less than a first reference value (e.g., 0.1) for determining whether or not the glucose uptake rate reaches a steady state. If the difference between the current glucose uptake rate and the previous glucose uptake rate is less than the first reference value (YES in step S308), the CPU 11a returns the process to the call address of the first glucose uptake rate estimating process in the main routine, and, if the difference is at least the first reference value (NO in step S308), the CPU 11a repeats the processes in step S302 and subsequent steps.
Next, the CPU 11a executes a second glucose uptake rate estimating process (step S4).
Next, the CPU 11a determines whether or not the glucose uptake rate in a hyperinsulinemic state obtained in the above-described process reaches a steady state (step S408). In this embodiment, this process is performed by obtaining a difference between the glucose uptake rate obtained in the current calculation (turn) and the glucose uptake rate in the previous calculation (turn) stored in the RAM 11c, and determining whether or not the difference is less than the first reference value (e.g., 0.1) for determining whether or not the glucose uptake rate reaches a steady state. Here, the configuration is adopted in which, in the first glucose uptake rate estimating process and the second glucose uptake rate estimating process, the same first reference value is used to determine whether or not the glucose uptake rate reaches the steady state, but this is not a limitation, and different reference values may be used in these respective processes. Then, if the difference between the current glucose uptake rate and the previous glucose uptake rate is less than the first reference value (YES in step S408), the CPU 11a returns the process to the call address of the second glucose uptake rate estimating process in the main routine, and, if the difference is at least the first reference value (NO in step S408), the CPU 11a repeats the processes in step S402 and subsequent steps.
Next, the CPU 11a calculates the muscle amount of the subject from the input body weight and skeletal muscle percentage of the subject (step S5), and calculates the glucose uptake rate per unit weight in a hyperinsulinemic state by multiplying this muscle amount, the glucose distribution amount (constant), and the glucose concentration obtained in the second glucose uptake rate estimating process by the glucose uptake (GLUT) obtained in the second glucose uptake rate estimating process (step S6). Next, the CPU 11a estimates the presence or absence of the insulin resistance (step S7). This process is performed by determining whether or not the glucose uptake rate (estimated value) per unit weight obtained in step S6 is at least a second reference value (e.g., 12 mg/kg/min) for estimating the presence or absence of the insulin resistance. Accordingly, if the estimated glucose uptake rate is at least the second reference value, it is possible to estimate that the insulin resistance is not present, that is, the insulin sensitivity is present. Furthermore, if the estimated glucose uptake rate is less than the second reference value, it is possible to estimate that the insulin resistance is present, that is, the insulin sensitivity is not present. In this manner, the CPU 11a estimates the insulin resistance.
Next, the CPU 11a displays an output screen for outputting the estimation results of the insulin resistance (step S8).
With this sort of configuration, it is possible to estimate the presence or absence of the insulin resistance using biological information including “body weight”, “amount of oxygen consumed per unit time in the skeletal muscle”, “amount of carbon dioxide produced per unit time in skeletal muscle”, “skeletal muscle percentage”, “fasting blood glucose concentration”, “fasting plasma insulin concentration”, and “fasting blood free fatty acid concentration” that can be obtained with a simple test without placing a heavy burden on the subject, instead of requiring test results of a glucose clamp test and an oral glucose tolerance test that place a heavy burden on the subject. Among these pieces of input information, regarding the fasting blood glucose concentration and plasma insulin concentration, test values easily obtained with a blood test can be used as described above, but test values obtained with a glucose clamp test or an oral glucose tolerance test may also be used as the input information. However, this system is useful in that results of tests such as a glucose clamp test and an oral glucose tolerance test that place a heavy burden on the subject are not always required and results of a simple blood test can also be used instead of such test results, and in that information used as the input information can be obtained from any of the blood test, the glucose clamp test, and the oral glucose tolerance test.
Furthermore, suppression of the rate of acetyl-CoA produced in the β-oxidization due to the malonyl-CoA concentration is taken into consideration, and the rate of acetyl-CoA produced in the β-oxidization is adjusted due to the malonyl-CoA concentration obtained based on the acetyl-CoA concentration, and the glucose metabolizing function in an actual living body is precisely reproduced. Also from this aspect, it can be expected to obtain estimated values precisely reflecting the actual glucose uptake rate.
Furthermore, based on the above-described biological information, the glucose metabolizing function in the actual living organ is virtually reproduced, and an estimated glucose uptake rate is obtained. Thus, it can be expected to obtain estimated values precisely reflecting the actual glucose uptake rate. Furthermore, in this embodiment, the glucose uptake rate in a hyperinsulinemic state is estimated, and this estimated value is output. In a glucose clamp test, glucose and insulin are injected to the subject such that the hyperinsulinemic state is maintained. Furthermore, the glucose uptake rates disclosed in documents and the like are normally values in a hyperinsulinemic state. Accordingly, by estimating a glucose uptake rate in a hyperinsulinemic state as described above and outputting this estimated value, the user can compare the estimated value with results of a glucose clamp test or values reported in documents and the like, and the insulin resistance of that subject can be easily evaluated.
Furthermore, in this embodiment, the glucose uptake rate per unit weight is estimated, and this estimated value is output. In a glucose clamp test, the glucose uptake rates per unit weight are obtained. Furthermore, the glucose uptake rates disclosed in documents and the like are normally values per unit weight. Accordingly, by estimating a glucose uptake rate per unit weight as described above and outputting this estimated value, the user can compare the estimated value with results of a glucose clamp test or values reported in documents and the like, and the insulin resistance of that subject can be easily evaluated.
This embodiment relates to an insulin resistance evaluation supporting system that receives input of information relating to a glucose concentration, an insulin concentration, and a free fatty acid concentration in blood obtained by measuring a subject, estimates a glucose uptake rate of the subject based on the information relating to the glucose concentration, the insulin concentration, and the free fatty acid concentration in the blood whose input has been received, estimates insulin resistance of the subject based on the estimated glucose uptake rate, and outputs a result of the estimation.
The CPU 211a can execute computer programs loaded into the RAM 211c. Execution of an insulin resistance evaluation supporting program 214a as described later by the CPU 211a allows the computer 201a to function as the insulin resistance evaluation supporting system 201.
The RAM 11c is configured from an SRAM, a DRAM, or the like. The RAM 11c is used to read the insulin resistance evaluation supporting program 214a stored in the hard disk 211d. Furthermore, the RAM 11c is used as a work area of the CPU 211a when the CPU 211a executes a computer program.
On the hard disk 211d, various computer programs (e.g., operating systems and application programs) that are to be executed by the CPU 211a and data used for the execution of the computer programs are installed. The insulin resistance evaluation supporting program 214a described later is also installed on the hard disk 211d.
The reading device 211e is configured from a flexible disk drive, a CD-ROM drive, a DVD-ROM drive, or the like, and can read computer programs or data stored in a portable storage medium 214. Furthermore, the portable storage medium 214 stores the insulin resistance evaluation supporting program 214a for causing a computer to function as an insulin resistance evaluation supporting system. The computer 201a can read the insulin resistance evaluation supporting program 214a from the portable storage medium 214, and install the insulin resistance evaluation supporting program 214a on the hard disk 211d.
Here, the insulin resistance evaluation supporting program 214a does not necessarily have to be provided by the portable storage medium 214, and can be provided through an electric telecommunication line (it may be either wired or wireless) from an external apparatus communicably connected via the electric telecommunication line to the computer 201a. For example, it is possible that the insulin resistance evaluation supporting program 214a is stored in a hard disk of a server computer on the Internet, and the computer 201a accesses the server computer to download and install the computer program on the hard disk 211d.
Furthermore, on the hard disk 211d, for example, a multi-task, operating system such as Windows (registered trademark) manufactured and marketed by Microsoft Corporation (U.S.) is installed. In the following description, it is assumed that the insulin resistance evaluation supporting program 214a according to this embodiment operates on the operating system. The configuration of the insulin resistance evaluation supporting program 214a will be described later in detail.
Here, the other portions of the configuration of the computer 201a according to Embodiment 2 are the same as those of the configuration of the computer 1a according to Embodiment 1, and, thus, a description thereof is omitted.
Next, the insulin resistance evaluation supporting program 214a will be described in more detail.
The fatty acid metabolism block 221 is a functional block virtually reproducing a function of metabolizing fatty acid in a living organ such as muscle tissues or adipose tissues. The fatty acid metabolism function of the body causes blood free fatty acid to be taken up into the cell, produces fatty acyl-coenzyme A complex (FAC) from the free fatty acid (FFA), and produces triglyceride (TG) via diacylglycerol (DG). The fatty acid metabolism block 221 represents such a fatty acid metabolism function of the body. Execution of the fatty acid metabolism block 221 by the CPU 11a allows the reaction rate fGA3P→DG of producing DG from FAC and D-glyceraldehyde 3-phosphate (GA3P), the reaction rate fDG→TG of producing TG from DG and FAC, the reaction rate fTG→DG of producing DG and FFA from TG, the reaction rate fDG→FFA of producing FFA and glycerol (GLR) from DG, and the reaction rate fFFA→FAC of producing FAC from FFA to be calculated, and the intracellular concentrations of FFA, GLR, DG, TG, FAC and FAC after a specific period of time to be calculated.
Hereinafter, a chemical reaction relating to the fatty acid metabolism function of the living organ such as muscle tissues or adipose tissues and a specific calculation process of the fatty acid metabolism block 221 based thereon will be described. Here, the intracellular concentrations of FFA, FAC, DG, TG, GA3P, GLR, ATP, ADP, NAD, NADH, and inorganic phosphate (Pi) in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations.
First, blood fatty acid (FFA) is taken up into a cell. The uptake rate fFFA is represented by Formula (52) below.
f
FFA
=Q·(CFFA,b−σFFA·CFFA) (52)
In the formula, CFFA,b refers to the input blood fatty acid concentration, CFFA refers to the intracellular fatty acid concentration, σFFA refers to a distribution coefficient relating to fatty acid, and Q refers to the blood flow rate in the muscle tissue.
Next, blood glycerol (GLR) is taken up into the cell. The uptake rate fGLC is represented by Formula (53) below.
f
GLR
=Q·(CGLR,b−σGLR·CGLR) (53)
In the formula, CGLR,b refers to the input blood glycerol concentration, CGLR refers to the intracellular glycerol concentration, and σGLC refers to a distribution coefficient relating to glycerol.
Then, FAC is synthesized using ATP from the fatty acid (FFA) flown into the cell and CoA according to Formula (8) of Embodiment 1. The rate of this reaction is represented by Formula (54) below.
Next, DG is synthesized via a plurality of reactions from the GA3P in the glycolysis block and the produced FAC.
GA3P+2FAC+NADH→DG+2CoA+Pi+NAD (55)
The rate of this reaction is represented by Formula (56) below.
Next, TG is produced from DG and FAC.
DG+FAC→TG+CoA (57)
The rate of this reaction is represented by Formula (58) below.
As shown in the following formula, hormone-sensitive lipase (HSL) or the like causes the triglyceride (TG) to decompose into DG and FFA.
TG→DG+FFA (59)
The rate of this reaction is represented by Formula (60) below.
Here, HSL(insulin) is calculated in the insulin signaling block 222.
HSL or the like causes the DG to decompose into FFA and GLR.
DG→GLR+2FFA (61)
The rate of this reaction is represented by Formula (62) below.
In the fatty acid metabolism block 221, the CPU 211a calculates the reaction rates fFFA, fGLC, fFFA→FAC, fGA3P→DG, fDG→TG, fTG→DG, and fDG→GLR represented by Formulae (52), (53), (54), (56), (58), (60), and (62) above, respectively.
Furthermore, in the fatty acid metabolism block 221, the CPU 211a calculates the production rate of FFA represented by Formula (63) below, the production rate of FAC represented by Formula (64) below, the production rate of DG represented by Formula (65) below, the production rate of TG represented by Formula (66) below, and the production rate of GLC represented by Formula (67) below.
In Formula (64), the reaction rate fFAC→ACoA is represented by Formula (152) described later, and calculated in the mitochondria block 224. If no calculation has been performed in the mitochondria block 224, the initial value of the reaction rate fFAC→ACoA is used.
Furthermore, in the fatty acid metabolism block 221, the CPU 211a calculates the amounts of FFA, FAC, DG, TG, and GLR produced in a specific period of time respectively from the thus obtained rates of FFA, FAC, DG, TG, and GLR produced, and reflects these amounts on the intracellular FFA concentration, FAC concentration, DG concentration, TG concentration, and GLR concentration at that time, thereby calculating the intracellular FFA concentration, FAC concentration, DG concentration, TG concentration, and GLR concentration after the specific period of time.
Furthermore, as described later, the fatty acid metabolism block 221 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the fatty acid metabolism block 221 is used to perform a process that calculates the intracellular glucose concentration, FFA concentration, FAC concentration, DG concentration, TG concentration, and GLC acid concentration in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the fatty acid metabolism block 221 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
The insulin signaling block 222 is a functional block virtually reproducing a function of adjusting the appearance amount of glucose transporter (GLUT4) that is known to appear in a living organ, in particular, muscle tissues and adipose tissues. The function of adjusting the GLUT4 appearance amount in a living body adjusts the ratio of glucose transporter (GLUT4) occupying the cell membrane according to the amount of insulin binding to insulin receptors and the concentration of diacylglycerol (DG) formed as a metabolite of the fatty acid metabolism. The insulin signaling block 222 according to this embodiment represents such a function of adjusting the ratio of GLUT4 occupying the cell membrane in the body, and the enzymes including hexokinase (HK), glycogen synthase (GS), pyruvate dehydrogenase (PDH), and hormone-sensitive lipase (HSL), and fatty acid oxidization on which insulin is known to act. Execution of the insulin signaling block 222 by the CPU 211a allows a value according to the GLUT4 appearance amount, and the activation of the enzymes HK, GS, PDH, and HSL and the fatty acid oxidization to be calculated based on the plasma insulin concentration (PI) and the DG concentration.
Hereinafter, a specific calculation process of the insulin signaling block 222 based on the function of adjusting the GLUT4 appearance amount on the cell membrane in the living organ will be described. The function of adjusting the GLUT4 appearance amount in the living organ is characterized in that, as the plasma insulin concentration is increased, the GLUT4 appearance amount is increased, and, as the FAC concentration and the DG concentration are increased, the GLUT4 appearance amount is suppressed. In consideration of these characteristics, in the insulin signaling block 222, a glucose uptake (GLUT), which is a value according to the GLUT4 appearance amount, is calculated following Formulae (68) to (131) below using the input plasma insulin concentration and the DG concentration obtained through the calculation in the fatty acid metabolism block 221.
The transition rate fx2→x3 from insulin receptors on the cell membrane binding to no insulin to insulin receptors on the cell membrane binding to one insulin molecule is determined by the plasma insulin concentration X1, the concentration X2 of the insulin receptors on the cell membrane binding to no insulin, and the reaction rate constant k1 as shown in Formula (68) below.
fx2→x3=k1x1x2 (68)
k
1=6×107M−1·min−1
The transition rate fx3→x2 from insulin receptors on the cell membrane binding to one insulin molecule to insulin receptors on the cell membrane binding to no insulin is determined by the concentration x3 of the insulin receptors on the cell membrane binding to one insulin molecule and the reaction rate constant k−1 as shown in Formula (69) below.
fx3→x2=k−1x3 (69)
k−1=0.20 min−1
The transition rate fx3→x5 from insulin receptors on the cell membrane binding to one insulin molecule to insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation is determined by the concentration x3 of the insulin receptors on the cell membrane binding to one insulin molecule and the reaction rate constant k3 as shown in Formula (70) below.
fx3→x5=k3x3 (70)
k3=2500 min−1
The transition rate fx5→x2 from insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation to insulin receptors on the cell membrane binding to no insulin is determined by the concentration x5 of the insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation, the protein tyrosine phosphatase (PTP), and the reaction rate constant k3 as shown in Formula (71) below.
The transition rate fx5→x4 from insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation to insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation is determined by the concentration x5 of the insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation and the reaction rate constant k2 as shown in Formula (72) below.
fx5→x4=k2x5 (72)
k2=k1
The transition rate fx4→x5 from insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation to insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation is determined by the concentration x4 of the insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation and the reaction rate constant k2 as shown in Formula (73) below.
fx4→x5=k−2x4 (73)
k−2=100k1
The transition rate fx2→x6 from insulin receptors on the cell membrane binding to no insulin to insulin receptors binding to no insulin in the cell is determined by the concentration x2 of the insulin receptors on the cell membrane binding to no insulin and the reaction rate constant k4 as shown in Formula (74) below.
The transition rate fx6→x2 from insulin receptors binding to no insulin in the cell to insulin receptors on the cell membrane binding to one insulin molecule is determined by the concentration x6 of the insulin receptors binding to no insulin in the cell and the reaction rate constant k4 as shown in Formula (75) below.
fx6→x2=k−4x6 (75)
k−4=0.003 min−1
The transition rate fx5→x8 from insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation to insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation is determined by the concentration x5 of the insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation and the reaction rate constant k4, as shown in Formula (76) below.
fx5→x8=k4′x5 (76)
k
4′=2.1×10−3 m
The transition rate fx8→x5 from insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation to insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation is determined by the concentration x8 of the insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation and the reaction rate constant k−4, as shown in Formula (77) below.
fx8→x5=k−4′x8 (77)
k
−4′=2.1×10−4I
The transition rate fx4→x7 from insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation to insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation is determined by the concentration x4 of the insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation and the reaction rate constant k4′, as shown in Formula (78) below.
fx4→x7=k4′x4 (78)
The transition rate fx7→x4 from insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation to insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation is determined by the concentration x7 of the insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation and the reaction rate constant k−4′, as shown in Formula (79) below.
fx7→x4=k−4′x7 (79)
The transition rate fx7→x6 from insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation to insulin receptors binding to no insulin in the cell is determined by the concentration x7 of the insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation, the protein tyrosine phosphatase (PTP), and the reaction rate constant k6 as shown in Formula (80) below.
The transition rate fx8→x6 from insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation to insulin receptors binding to no insulin in the cell is determined by the concentration x8 of the insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation, the protein tyrosine phosphatase (PTP), and the reaction rate constant k6 as shown in Formula (81) below.
fx8→x6=k6[PTP]x8 (81)
It is assumed that the rate of producing an insulin receptor in the cell is a constant value indicated as a constant k5 as shown in Formula (82) below.
f→x6=k5 (82)
k
5=10k−5M·min−1 if (x6+x7+x8)>1×10−13
k
5=60k−5M·min−1 if (x6+x7+x8)≦1×10−13
The decomposition rate fx6→ of the insulin receptors binding to no insulin in the cell is determined by the concentration x6 of the insulin receptors binding to no insulin in the cell and the reaction rate constant k−5 as shown in Formula (83) below.
fx6→=k−5x6 (83)
k
−5=1.67×10−18 min−1
The transition rate fx9→x10 from an unphosphorylated insulin receptor substrate 1 (IRS1) to a tyrosine-phosphorylated insulin receptor substrate 1 is determined by the concentration x9 of the unphosphorylated insulin receptor substrate 1, the concentration x4 of the insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation, the concentration X5 of the insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation, and the reaction rate constant k7 of tyrosine phosphorylation as shown in Formula (84) below.
f
x9→x10
=k
7
x
9(x4+x5)/IRp (84)
k7=4.16 min−1
In the formula, IRP refers to the phosphorylated insulin receptor concentration on the cell membrane under the maximum insulin stimulation.
The transition rate fx10→x9 from a tyrosine-phosphorylated insulin receptor substrate 1 to an unphosphorylated insulin receptor substrate 1 (IRS1) is determined by the concentration x10 of the tyrosine-phosphorylated insulin receptor substrate 1, the protein tyrosine phosphatase (PTP), and the reaction rate constant k7 of the dephosphorylation as shown in Formula (85) below.
The transition rate fx9→x10a from an unphosphorylated insulin receptor substrate 1 (IRS1) to a serine-phosphorylated insulin receptor substrate 1 is determined by the concentration x9 of the unphosphorylated insulin receptor substrate 1, the protein kinase C (PKC), and the reaction rate constant k7′ of the serine phosphorylation as shown in Formula (86) below.
The transition rate fx10a→x9 from a serine-phosphorylated insulin receptor substrate 1 to an unphosphorylated insulin receptor substrate 1 (IRS1) is determined by the concentration x10a of the serine-phosphorylated insulin receptor substrate 1 and the reaction rate constant k−7′ of the dephosphorylation as shown in Formula (87) below.
The rate fx10→x12 of producing a complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) from a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) is determined by the concentration x10 of the serine-phosphorylated insulin receptor substrate 1, the concentration x11 of the phosphatidylinositol 3-kinase (PI3K), and the rate constant k8 as shown in Formula (88) below.
The rate fx12→x10 of producing a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) from the complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) is determined by the concentration x12 of the complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) and the rate constant k8 as shown in Formula (89) below.
fx12→x10=k−8x12 (89)
k−8=10.0 min−1
The rate fx13→x15 of dephosphorylation from phosphatidylinositol (3,4,5)-trisphosphate into phosphatidylinositol (3,4)-bisphosphate using 5′-lipid phosphatase such as Src homology 2 containing inositol 5′ phosphatase (SHIP) is determined by the ratio x13 of the phosphatidylinositol (3,4,5)-trisphosphate, the SHIP concentration, and the rate constant k−10 as shown in Formula (90) below.
fx13→x15=k−10[SHIP]x13 (90)
k−10=2.77 min−1
[SHIP]=1.00
The rate fx5→x13 of phosphorylation from phosphatidylinositol (3,4)-bisphosphate into phosphatidylinositol (3,4,5)-trisphosphate is determined by the ratio x15 of the phosphatidylinositol (3,4)-bisphosphate and the rate constant k10 as shown in Formula (91) below.
The rate fx13→x14 of dephosphorylation from phosphatidylinositol (3,4,5)-trisphosphate into phosphatidylinositol (4,5)-bisphosphate using 3′-lipid phosphatase such as phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is determined by the ratio x13 of the phosphatidylinositol (3,4,5)-trisphosphate, the PTEN concentration, and the rate constant k9 as shown in Formula (92) below.
In the formula, k9 (stimulated) refers to a constant relating to the rate fx14→x13 of phosphorylation from phosphatidylinositol (4,5)-bisphosphate into phosphatidylinositol (3,4,5)-trisphosphate, and relates to a component depending on the complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) at that rate.
The rate fx14→x13 of phosphorylation from phosphatidylinositol (4,5)-bisphosphate into phosphatidylinositol (3,4,5)-trisphosphate is determined by the ratio x14 of the phosphatidylinositol (4,5)-bisphosphate and the rate constant k9 as shown in Formula (93) below.
In the formula, k9(basal) refers to a constant relating to the rate fx14→x13 of phosphorylation from phosphatidylinositol (4,5)-bisphosphate into phosphatidylinositol (3,4,5)-trisphosphate, and relates to a component not depending on the complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) at that rate.
The rate fx16→x17 of phosphorylation from unphosphorylated AKT into phosphorylated AKT is determined by the unphosphorylated AKT ratio x16 and the rate constant k11 as shown in Formula (94) below.
The rate fx17→x16 of dephosphorylation from phosphorylated AKT into unphosphorylated AKT is determined by the phosphorylated AKT ratio x17 and the rate constant k−11 as shown in Formula (95) below.
fx17→x16=k−11x17 (95)
k
−11=10 ln(2)min−1
The rate fx18→x19 of phosphorylation from unphosphorylated PKC into phosphorylated PKC is determined by the unphosphorylated PKC ratio x18 and the rate constant k12 as shown in Formula (96) below.
The rate fx19→x18 of dephosphorylation from phosphorylated PKC into unphosphorylated PKC is determined by the phosphorylated PKC ratio x19 and the rate constant k−12 as shown in Formula (97) below.
fx19→x18=k−12x19 (97)
k
−12=10 ln(2)min−1
The rate f→x20 of producing GLUT4 in the cell is determined by the production rate k14 as shown in Formula (98) below.
f→x20=k14 (98)
k14=96k−14
The decomposition rate fx20→ of GLUT4 in the cell is determined by the ratio x20 of the GLUT4 in the cell and the rate constant k−14 as shown in Formula (99) below.
fx20→=k−14x20 (99)
k−14=0.001155 min−1
The translocation rate fx20→x21 from glucose transporter GLUT4 in the cell to GLUT4 on the cell membrane is determined by the ratio x20 of the GLUT4 in the cell and the rate constants k13 and k13′ as shown in Formula (100) below.
The translocation rate fx21→x20 from glucose transporter GLUT4 on the cell membrane to GLUT4 in the cell is determined by the ratio x21 of the GLUT4 on the cell membrane and the rate constant k−13 as shown in Formula (101) below.
fx21→x20=k−13x21 (101)
k−13=0.167 min−1
The activation rate fx22→x23 from inactive enzymes into activated enzymes is determined by the enzyme activity auxiliary variable x22 and the rate constant k15 as shown in Formula (102) below.
The inactivation rate fx23→x22 from activated enzymes into inactive enzymes is determined by the enzyme activity auxiliary variable x23 and the rate constant k−15 as shown in Formula (103) below.
fx23→x22=k−15x23 (103)
k−15=0.01 min−1
The value of activated hexokinase (HK) is calculated using Formula (104) below.
HK(insulin)=0.2339x23 (104)
The value of activated glycogen synthase (GS) is calculated using Formula (105) below.
GS(insulin)=0.52x23+0.134817 (105)
The value of activated pyruvate dehydrogenase (PDH) is calculated using Formula (106) below.
PDH(insulin)=0.37643x23+0.56191 (106)
The value of activated hormone-sensitive lipase (HSL) is calculated using Formula (107) below.
HSL(insulin)=1.0−0.12174x3 (107)
The value of activated hydroxyacyl dehydrogenase (HAD) is calculated using Formula (108) below.
HAD(insulin)=1.0−0.12174x23 (108)
Furthermore, in the insulin signaling block 222, the production rate of insulin receptors on the cell membrane binding to no insulin represented by Formula (109) below, the production rate of insulin receptors on the cell membrane binding to one insulin molecule represented by Formula (110) below, the production rate of insulin receptors on the cell membrane binding to one insulin molecule and activated by phosphorylation represented by Formula (111) below, the production rate of insulin receptors on the cell membrane binding to two insulin molecules and activated by phosphorylation represented by Formula (112) below, the production rate of insulin receptors binding to no insulin in the cell represented by Formula (113) below, the production rate of insulin receptors binding to one insulin molecule in the cell and activated by phosphorylation represented by Formula (114) below, the production rate of insulin receptors binding to two insulin molecules in the cell and activated by phosphorylation represented by Formula (115) below, the production rate of an unphosphorylated insulin receptor substrate 1 (IRS1) represented by Formula (116) below, the production rate of a tyrosine-phosphorylated insulin receptor substrate 1 represented by Formula (117) below, the production rate of a serine-phosphorylated insulin receptor substrate 1 represented by Formula (118) below, the production rate of a phosphatidylinositol 3-kinase (PI3K) represented by Formula (119) below, the production rate of a complex of a serine-phosphorylated insulin receptor substrate 1 and a phosphatidylinositol 3-kinase (PI3K) represented by Formula (120) below, the production rate of phosphatidylinositol (3,4,5)-trisphosphate represented by Formula (121) below, the production rate of phosphatidylinositol (3,4)-bisphosphate represented by Formula (122) below, the production rate of phosphatidylinositol (4,5)-bisphosphate represented by Formula (123) below, the production rate of unphosphorylated AKT represented by Formula (124) below, the production rate of phosphorylated AKT represented by Formula (125) below, the production rate of unphosphorylated PKC represented by Formula (126) below, the production rate of phosphorylated PKC represented by Formula (127) below, the production rate of intracellular glucose transporter (GLUT4) represented by Formula (128) below, the production rate of glucose transporter (GLUT4) on the cell membrane represented by Formula (129) below, the enzyme activity auxiliary variable x22 represented by Formula (130) below, and the enzyme activity auxiliary variable x23 represented by Formula (131) below are calculated.
Furthermore, as described later, the insulin signaling block 222 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the insulin signaling block 222 is used to perform a process that calculates the glucose uptake GLUT in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the insulin signaling block 222 is used to perform a process that calculates the glucose uptake GLUT in a hyperinsulinemic state.
The glycolysis block 223 is a functional block virtually reproducing a function of causing glucose to decompose in a living organ. The glucose decomposition function of the body causes glucose to be taken up into the cell according to the ratio of glucose transporter (GLUT4) occupying the cell membrane and causes the glucose in the cell to decompose to give pyruvic acid (PYR) via glucose 6-phosphate (G6P), D-glyceraldehyde 3-phosphate (GA3P), and 1,3-bisphosphoglycerate (BPG). Furthermore, this function produces lactic acid (LAC) from pyruvic acid (PYR). The glycolysis block 223 represents such a glucose decomposition function of the body. Execution of the glycolysis block 223 by the CPU 211a allows the glucose uptake rate to be calculated based on the glucose uptake GLUT obtained in the insulin signaling block 222 and the rate of oxygen consumed and the rate of carbon dioxide produced in the tissue, and the reaction rate fGLU→G6P of converting glucose into G6P, the reaction rate fG6P→GA3P of converting G6P into GA3P, the reaction rate fGA3P→BPG of converting GA3P into BPG, the reaction rate fBPG→PYR of converting BPG into PYR, the reaction rate fPYR→LAC of converting PYR into LAC, and the reaction rate fLAC→PYR of converting LAC into PYR to be calculated. Furthermore, the glucose (GLU) concentration, the G6P concentration, the GA3P concentration, the BPG concentration, the PYR concentration, and the LAC concentration after a specific period of time are calculated based on these reaction rates.
Hereinafter, a chemical reaction relating to the glucose decomposition function of the living organ and a specific calculation process of the glycolysis block 223 based thereon will be described. Here, the intracellular concentrations of glucose, G6P, GA3P, BPG, pyruvic acid, LAC, NAD, and NADH in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations.
First, blood glucose is taken up into the cell according to the GLUT4 appearance amount (appearance amount on the cell surface). This uptake rate fGLU is represented by Formula (132) below.
f
GLU
=Q·GLUT·(CGLU,b−σGLU·CGLU) (132)
In the formula, CGLU,b refers to the input blood glucose concentration, CGLU refers to the intracellular glucose concentration, and σGLU refers to a distribution coefficient relating to glucose.
Blood lactic acid (LAC) is taken up into the cell. The uptake rate fLAC is represented by Formula (133) below.
f
LAC
=Q·(CLAC,b−σLAC·CLAC) (133)
In the formula, CLAC,b refers to the input blood lactic acid concentration, CLAC refers to the intracellular lactic acid concentration, and σLAC refers to a distribution coefficient relating to lactic acid.
Blood pyruvic acid (PYR) is taken up into the cell. The uptake rate fPYR is represented by Formula (134) below.
f
PYR
=Q·(CPYR,b−σPYR·CPYR) (134)
In the formula, CPYR,b refers to the input blood pyruvic acid concentration, CPYR refers to the intracellular pyruvic acid concentration, and σPYR refers to a distribution coefficient relating to pyruvic acid.
The glucose (GLU) taken up into the cell is phosphorylated by hexokinase to give G6P (Formula (17)). The rate of this reaction is represented by Formula (135) below.
In the formula, HK(insulin) is calculated in the insulin signaling block 222.
Furthermore, the G6P produced by the conversion reacts with ATP to give GA3P and ADP as shown in Formula (19). The rate of this reaction is represented by Formula (136) below.
The GA3P produced by the conversion is converted to 1,3-bisphosphoglycerate (BPG) according to Formula (137) below.
GA3P+Pi+NAD→BPG+NADH (137)
The reaction rate of the conversion to is represented by Formula (138) below.
The BPG produced by the conversion is converted to pyruvic acid (PYR) according to Formula (139) below.
BPG+2ADP→PYR+2ATP (139)
The reaction rate of the conversion to PYR is represented by Formula (140) below.
The produced pyruvic acid (PYR) is converted to lactic acid (LAC) according to Formula (141) below.
PYR+NADH→LAC+NAD (141)
The reaction rate is represented by Formula (142) below.
The lactic acid (LAC) is converted to pyruvic acid (PYR) according to Formula (143) below.
LAC+NAD→PYR+NADH (143)
The reaction rate is represented by Formula (144) below.
In the glycolysis block 223, the CPU 211a calculates the reaction rates fGLU, fLAC, fPYR, fGLU→G6P, fG6P→GA3P, fGA3P→BPG, fBPG→PYR, fPYR→LAC, and fLAC→PYR represented by Formulae (132), (133), (134), (135), (136), (138), (140), (142), and (144) above, respectively.
Furthermore, in the glycolysis block 223, the CPU 211a calculates the production rate of glucose represented by Formula (145) below, the production rate of G6P represented by Formula (146) below, the production rate of GA3P represented by Formula (147) below, the production rate of BPG represented by Formula (148) below, the production rate of pyruvic acid represented by Formula (149) below, and the production rate of lactic acid represented by Formula (150) below.
In Formula (149), the reaction rate fPYR→ACoA is represented by Formula (151) described later, and calculated in the mitochondria block 224. The reaction rate fPYR→ALA is calculated in a supplemental calculation process. If no calculation has been performed in the mitochondria block 224 and the supplemental calculation process, the initial values of the reaction rates fPYR→ACoA and fPYR→ALA are used.
Furthermore, in the glycolysis block 223, the CPU 211a calculates the amounts of glucose, G6P, GA3P, BPG, pyruvic acid, and lactic acid produced in a specific period of time respectively from the thus obtained rates of glucose, G6P, GA3P, BPG, pyruvic acid, and lactic acid produced, and reflects these amounts on the intracellular glucose concentration, G6P concentration, GA3P concentration, BPG concentration, and pyruvic acid concentration at that time, thereby calculating the intracellular glucose concentration, G6P concentration, GA3P concentration, BPG concentration, and pyruvic acid concentration after the specific period of time.
Furthermore, as described later, the glycolysis block 223 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the glycolysis block 223 is used to perform a process that calculates the intracellular glucose concentration, G6P concentration, GA3P concentration, BPG concentration, pyruvic acid concentration, and lactic acid concentration in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the glycolysis block 223 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
The mitochondria block 224 is a functional block virtually reproducing a function of mitochondria in a living organ. The mitochondria produce acetyl coenzyme A (ACoA) by oxidizing the pyruvic acid (PYR) and the fatty acyl-coenzyme A complex (FAC), and convert the acetyl coenzyme A (ACoA) to H2O and CO2 through metabolism in the TCA cycle. Fatty acid oxidization is suppressed according to the acetyl coenzyme A (ACoA) concentration. The mitochondria block 224 represents such a mitochondria function. Execution of the mitochondria block 224 by the CPU 211a allows the reaction rate fPYR→ACoA of producing acetyl coenzyme A (ACoA) from the pyruvic acid obtained in the glycolysis block 223, the reaction rate fFAC→ACoA of producing acetyl coenzyme A (ACoA) from the fatty acyl-coenzyme A complex (FAC) obtained in the fatty acid metabolism block 221, the reaction rates fACoA→CIT, fCIT→aKG, faKG→SCoA, fSCoA→SUC, fSUC→MAL, and fMAL→OxA, of producing citric acid (CIT) from acetyl coenzyme A (ACoA) and oxaloacetic acid (OXA), and sequentially metabolizing the resultant to produce α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), and oxaloacetic acid (OXA) in this order, and the reaction rate fO2→H2O of consuming oxygen and producing water to be calculated. Furthermore, the intracellular concentrations of acetyl coenzyme A (ACoA), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxaloacetic acid (OXA), oxygen (O2), and carbon dioxide (CO2) after a specific period of time are calculated based on these reaction rates.
Hereinafter, a biochemical reaction relating to the mitochondria and a specific calculation process of the mitochondria block 224 based thereon will be described. Here, the intracellular concentrations of acetyl coenzyme A (ACoA), coenzyme A (CoA), oxygen (O2), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxaloacetic acid (OXA), and carbon dioxide (CO2) in the following formulae are each provided with predetermined initial values. The initial value is used in the first calculation, and an updated value is used in the subsequent calculations.
First, intracellular pyruvic acid (PYR) is oxidized to give acetyl coenzyme A (ACoA) (Formula (27)). The rate of this reaction is represented by Formula (151) below.
In the formula, PDH(insulin) is calculated in the insulin signaling block 222.
Furthermore, the fatty acyl-coenzyme A complex (FAC) produced in the fatty acid metabolism block 221 is oxidized to give acetyl coenzyme A (ACoA) as shown in Formula (29) β-oxidization). The rate of this reaction is represented by Formula (152) below.
In the formula, HAD(insulin) is calculated in the insulin signaling block 222.
The acetyl-coenzyme A (ACoA) complex produced from pyruvic acid (PYR) and fatty acyl-coenzyme A complex (FAC) is metabolized in the TCA cycle represented by the series of formulae shown below, and ATP and NADH are newly produced. In the TCA cycle, citric acid (CIT) is produced from oxaloacetic acid (OXA) and acetyl-CoA, and then α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), and oxaloacetic acid (OXA) are produced and metabolized in this order.
First, ACoA and OXA are converted by citrate synthase to CIT and CoA (Formula (153)).
ACoA+OXA→CIT+CoA (153)
The rate of this reaction is represented by Formula (154) below.
The reaction process in which α-ketoglutaric acid (aKG) is produced from citric acid (CIT) via cis-aconitic acid, isocitric acid, and oxalosuccinic acid can be simply represented by the following formula.
CIT+NAD→aKG+NADH+CO2 (155)
The rate of this reaction is represented by Formula (156) below.
The α-ketoglutaric acid (aKG) is oxidized to give succinyl-CoA (SCoA) and carbon dioxide (CO2) (Formula (157)).
aKG+CoA+NAD→SCoA+NADH+CO2 (157)
The rate of this reaction is represented by Formula (158) below.
Succinic acid (SUC) is produced from the succinyl-CoA (SCoA) by succinyl-CoA synthetase (Formula (159)).
SCoA+ADP+Pi→SUC+CoA+ATP (159)
The rate of this reaction is represented by Formula (160) below.
Malic acid (MAL) is produced from the succinic acid (SUC) via fumaric acid (Formula (161)).
The rate of this reaction is represented by Formula (162) below.
The malic acid (MAL) is oxidized by malate dehydrogenase to give oxaloacetic acid (OXA) (Formula (163)).
MAL+NAD→OXA+NADH (163)
The rate of this reaction is represented by Formula (164) below.
Meanwhile, the relationship between the consumption of NADH, oxygen, and ADP and the synthesis of ATP in the mitochondria is represented by Formula (165) below.
O2+5.64ADP+5.64Pi+1.88NADH→2H2O+5.64ATP+1.88NAD (165)
The rate of this reaction is represented by Formula (166) below.)
The inflow rate fO2 of oxygen into the cell can also be represented by Formula (167) below.
f
O2
=Q·(CO2,b−σO2·CO2) (167)
In the formula, CO2,b refers to the blood oxygen concentration (constant), CO2 refers to the intracellular oxygen concentration, and σO2 refers to a distribution coefficient relating to oxygen.
In a similar manner, the rate fCO2 of carbon dioxide produced in the cell can also be represented by Formula (168) below.
f
CO2
=Q·(CCO2−σCO2·CCO2) (168)
In the formula, CCO2,b refers to the blood carbon dioxide concentration (constant), CCO2 refers to the intracellular carbon dioxide concentration, and σCO2 refers to a distribution coefficient relating to carbon dioxide.
In the mitochondria block 224, the CPU 211a calculates the reaction rates fPYR→ACoA, fFAC→ACoA, fACoA→CIT, fCIT→aKG, faKG→SCoA, fSCoA→SUC, fSUC→MAL, fMAL→OXA, fO2→H2O, fO2, and fCO2 represented by Formulae (151), (152), (154), (156), (158), (160), (162), (164), (166), (167), and (168) above, respectively.
Furthermore, in the mitochondria block 224, the CPU 211a calculates the production rate of acetyl coenzyme A (ACoA) represented by Formula (169) below, the production rate of citric acid (CIT) represented by Formula (170) below, the production rate of α-ketoglutaric acid (aKG) represented by Formula (171) below, the production rate of succinyl-CoA (SCoA) represented by Formula (172) below, the production rate of succinic acid (SUC) represented by Formula (173) below, the production rate of malic acid (MAL) represented by Formula (174) below, the production rate of oxaloacetic acid (OXA) represented by Formula (175) below, the production rate of oxygen (O2) represented by Formula (176) below, and the production rate of carbon dioxide (CO2) represented by Formula (177) below.
Furthermore, in the mitochondria block 224, the CPU 211a calculates the amounts of acetyl coenzyme A (ACoA), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxalo-acetic acid (OXA), oxygen (O2), and carbon dioxide (CO2) produced (consumed) in a specific period of time respectively from the thus obtained rates of acetyl coenzyme A (ACoA), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxaloacetic acid (OXA), oxygen (O2), and carbon dioxide (CO2) produced, and calculates the concentrations of the intracellular acetyl coenzyme A (ACoA), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxalo-acetic acid (OXA), oxygen (O2), and carbon dioxide (CO2) after the specific period of time.
Furthermore, as described later, the mitochondria block 224 is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the mitochondria block 224 is used to perform a process that calculates the concentrations of the intracellular acetyl coenzyme A (ACoA), citric acid (CIT), α-ketoglutaric acid (aKG), succinyl-CoA (SCoA), succinic acid (SUC), malic acid (MAL), oxaloacetic acid (OXA), oxygen (O2), and carbon dioxide (CO2) in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the mitochondria block 224 is used to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
Furthermore, the CPU 211a performs a supplemental calculation process as described below.
When the ADP concentration is high, a phosphoric acid group is removed from phosphocreatine (PCr) to give creatine (Cr), and ATP is produced from ADP (Formula (39)). The rate of this reaction is represented by Formula (178) below.
Meanwhile, as the ATP concentration is increased, creatine and ATP react with each other to give phosphocreatine and ADP (Formula (41)). The rate of this reaction is represented by Formula (179) below.
Furthermore, ATP is hydrolyzed and converted to ADP according to Formula (43). The rate of this reaction is represented by Formula (180) below.
Furthermore, ADP is produced from AMP and ATP by adenylate kinase (Formula (181)).
AMP+ATP→2ADP (181)
The rate of this reaction is represented by Formula (182) below.
AMP and ATP are produced from two ADPs by adenylate kinase (Formula (183)).
2ADP→AMP+ATP (183)
The rate of this reaction is represented by Formula (184) below.
The reaction formula in which G6P and ATP in the glycolysis block 223 are reacted via a plurality of processes to give glycogen (GLY) can be simply represented by the following formula.
G6P+ATP→GLY+ADP+2Pi (185)
The rate of this reaction is represented by Formula (186) below.
In the formula, GS(insulin) is calculated in the insulin signaling block 222.
The reaction formula in which glycogen (GLY) decomposes via a plurality of reactions to give G6P in the glycolysis block 223 can be simply represented by the following formula.
GLY→G6P+Pi (187)
The rate of this reaction is represented by Formula (188) below.
The reaction formula in which alanine (ALA) is produced from the pyruvic acid (PYR) produced in the glycolysis block 223 and glutamic acid can be simply represented by the following formula.
PYR→ALA (189)
The rate of this reaction is represented by Formula (190) below.
Blood alanine (ALA) is taken up into the cell. The uptake rate fALA is represented by Formula (191) below.
f
ALA
=Q·(CALA,b−σALA·CALA) (191)
In the formula, CALA,b refers to the input blood fatty acid concentration, CALA refers to the intracellular fatty acid concentration, and σALA refers to a distribution coefficient relating to fatty acid.
In the supplemental calculation process, the CPU 211a calculates the reaction rates fPCr→Cr, fCr→PCr, fATP→ADP, fAMP→ADP, fADP→AMP, fG6P→GLY, fGLY→G6P, fPYR→ALA, and fALA represented by Formulae (178), (179), (180), (182), (184), (186), (188), (190), and (191) above, respectively.
Furthermore, the CPU 211a calculates the production rates of substances GLY, ALA, NAD, NADH, ATP, ADP, Pi, PCr, Cr, and CoA according to Formulae (192) to (202) below. START HERE ***
Furthermore, the CPU 211a calculates the amounts of GLY, ALA, NAD, NADH, ATP, ADP, AMP, Pi, PCr, Cr, and CoA produced in a specific period of time respectively from the thus obtained rates of GLY, ALA, NAD, NADH, ATP, ADP, AMP, Pi, PCr, Cr, and CoA produced, and reflects these amounts on the intracellular concentrations of GLY, ALA, NAD, NADH, ATP, ADP, AMP, Pi, PCr, Cr, and CoA at that time, thereby calculating the intracellular concentrations of GLY, ALA, NAD, NADH, ATP, ADP, AMP, Pi, PCr, Cr, and CoA after the specific period of time.
Furthermore, as described later, the supplemental calculation process is used both in the first glucose uptake rate estimating process and in the second glucose uptake rate estimating process. In the first glucose uptake rate estimating process, the supplemental calculation process is executed to perform a process that calculates the intracellular concentrations of GLY, ALA, NAD, NADH, ATP, ADP, AMP, Pi, PCr, Cr, and CoA in a fasted state. Furthermore, in the second glucose uptake rate calculating process, the supplemental calculation process is executed to perform a process that calculates the intracellular concentrations of the substances in a hyperinsulinemic state.
The fatty acid metabolism block 221, the insulin signaling block 222, the glycolysis block 223, and the mitochondria block 224 according to this embodiment were formed with reference to the following documents.
1. A computational model of skeletal muscle metabolism linking cellular adaptations induced by altered loading states to metabolic responses during exercise.
2. Metabolic dynamics in skeletal muscle during acute reduction in blood flow and oxygen supply to mitochondria: in-silico studies using a multi-scale, top-down integrated model.
3. A mathematical model of metabolic insulin signaling pathways.
Next, an operation of the insulin resistance evaluation supporting system 201 according to this embodiment will be described.
After the insulin resistance evaluation supporting program 214a is started, first, the CPU 211a displays an input screen for prompting the user to input the body weight, the skeletal muscle percentage, the blood glucose concentration, the plasma insulin concentration, and the blood free fatty acid concentration of the subject (step S21).
Once input of the biological information and the execution instruction is received from the user, the CPU 211a executes a first glucose uptake rate estimating process (step S23).
Next, the CPU 211a determines whether or not the fasting glucose uptake rate obtained in the above-described process reaches a steady state (step S238). In this embodiment, this process is performed by obtaining a difference between the glucose uptake rate obtained in the current calculation (turn) and the glucose uptake rate in the previous calculation (turn) stored in the RAM 211c, and determining whether or not the difference is less than a first reference value for determining whether or not the glucose uptake rate reaches a steady state. If the difference between the current glucose uptake rate and the previous glucose uptake rate is less than the first reference value (YES in step S238), the CPU 211a returns the process to the call address of the first glucose uptake rate estimating process in the main routine, and, if the difference is at least the first reference value (NO in step S238), the CPU 211a repeats the processes in step S232 and subsequent steps.
Next, the CPU 211a executes a second glucose uptake rate estimating process (step S24).
Next, the CPU 211a determines whether or not the glucose uptake rate in a hyperinsulinemic state obtained in the above-described process reaches a steady state (step S248). In this embodiment, this process is performed by obtaining a difference between the glucose uptake rate obtained in the current calculation (turn) and the glucose uptake rate in the previous calculation (turn) stored in the RAM 211c, and determining whether or not the difference is less than the first reference value for determining whether or not the glucose uptake rate reaches a steady state. Here, the configuration is adopted in which, in the first glucose uptake rate estimating process and the second glucose uptake rate estimating process, the same first reference value is used to determine whether or not the glucose uptake rate reaches the steady state, but this is not a limitation, and different reference values may be respectively used in these processes. Then, if the difference between the current glucose uptake rate and the previous glucose uptake rate is less than the first reference value (YES in step S248), the CPU 211a returns the process to the call address of the second glucose uptake rate estimating process in the main routine, and, if the difference is at least the first reference value (NO in step S248), the CPU 211a repeats the processes in step S242 and subsequent steps.
Next, the CPU 211a estimates the presence or absence of the insulin resistance (step S25). This process is performed by determining whether or not the glucose uptake rate (estimated value) per unit muscle amount obtained in step S248 is at least a second reference value (e.g., 12.0 mg/kg/min if the insulin concentration during the glucose clamp is approximately 3480 pM, although it varies by race) for estimating the presence or absence of the insulin resistance. Accordingly, if the estimated glucose uptake rate is at least the second reference value, it is possible to estimate that the insulin resistance is not present, that is, the insulin sensitivity is present. Furthermore, if the estimated glucose uptake rate is less than the second reference value, it is possible to estimate that the insulin resistance is present, that is, the insulin sensitivity is not present. In this manner, the CPU 211a estimates the insulin resistance. Here, the second reference value is assumed to be 12.0 mg/kg/min based on the following documents.
Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia.
Next, the CPU 11a displays an output screen for outputting the estimation results of the insulin resistance (step S26). This output screen includes an insulin resistance estimation result obtained in the above-described process and a finally obtained estimated glucose uptake rate per unit muscle amount. With the output screen, the user is notified of the insulin resistance estimation result and the estimated glucose uptake rate. As the insulin resistance estimation result and the estimated glucose uptake rate are provided to the user in this manner, the user can use the information to perform evaluation of the insulin resistance. Furthermore, the display screen can be changed from this screen to a simulation result screen as described later. The configuration of the simulation result screen will be described later.
With this sort of configuration, it is possible to estimate the presence or absence of the insulin resistance using the biological information including “body weight”, “skeletal muscle percentage”, “fasting blood glucose concentration”, “fasting plasma insulin concentration”, and “fasting blood free fatty acid concentration” that can be obtained with a simple test without placing a heavy burden on the subject, instead of requiring test results of a glucose clamp test and an oral glucose tolerance test that place a heavy burden on the subject. Among these pieces of input information, regarding the fasting blood glucose concentration and plasma insulin concentration, test values easily obtained with a blood test can be used as described above, but test values obtained with a glucose clamp test or an oral glucose tolerance test may also be used as the input information. However, this system is useful in that results of tests such as a glucose clamp test and an oral glucose tolerance test that place a heavy burden on the subject are not always required and results of a simple blood test can also be used instead of such test results, and in that information used as the input information can be freely obtained from any of the blood test, the glucose clamp test, and the oral glucose tolerance test.
Here, in Embodiments 1 and 2 above, the configuration is adopted in which, in the second glucose uptake rate estimating process, the insulin concentration in a hyperinsulinemic state is set in order to reproduce the physical condition of the subject during a glucose clamp test, the glucose concentration is not changed from that in the first glucose uptake rate estimating process, and the fasting glucose concentration is used as it is, but this is not a limitation. A glucose clamp test that evaluates the insulin resistance is normally performed at a normal blood glucose level and a high insulin state. In a glucose clamp test, for example, there are cases in which insulin and glucose are administered to the subject such that the fasting blood glucose concentration is maintained or in which insulin and glucose are administered to the subject such that the blood glucose concentration is kept at 100 mg/dL. The latter case can be reproduced by not only setting an insulin concentration as found in a hyperinsulinemic state but also by setting a blood glucose concentration to be 100 mg/dL in the second glucose uptake rate estimating process.
Furthermore, in Embodiment 2, the configuration is adopted in which the glucose uptake rate per unit muscle amount is estimated and output, but the configuration may be adopted in which the glucose uptake rate per unit weight is obtained and output as in Embodiment 1.
Furthermore, in Embodiments 1 and 2, the configuration is adopted in which, until the glucose uptake rate reaches a steady state, the processes from the first metabolism amount calculation process to the supplemental calculation process are repeated, and the reaction rate, the production rate, and the intracellular concentration of each substance are repeatedly updated. Accordingly, when the glucose uptake rate reaches a steady state, the intracellular concentration of each substance is expected to be in a steady state, and the concentration of each substance in this steady state can be considered to reflect the physical condition of the subject. Accordingly, with this sort of configuration, it is possible to estimate the glucose uptake rate precisely reflecting the physical condition of the subject.
A performance evaluation experiment of the insulin resistance evaluation supporting system 201 according to Embodiment 2 was performed. One of the documents reporting result of glucose clamp tests is a report by Basu et al. (Basu et al., Obesity and Type 2 Diabetes Impair Insulin-Induced Suppression of Glycogenolysis as well as gluconeogenesis, Diabetes 54:1942-1948, 2005). The document by Basu et al. uses a glucose clamp test to perform a comparison between 10 non-diabetic lean-type subjects (Lean), 10 non-diabetic obese subjects (Obese), and 11 subjects suffering from type 2 diabetes (DM2), and mainly discusses the liver insulin resistance. In this experiment, data in the document was used, and a difference between the glucose appearance rate and the endogenous glucose production as a GIR value.
Table 1 below shows a summary of Lean, Obese, and DM2 measurement data shown in the above-described document.
In this experiment, first, the fasting blood glucose level, insulin level, and free fatty acid concentration of Lean, Obese, and DM2 measurement data shown in Table 1 above were input to the insulin resistance evaluation supporting system 201, and the concentration and the reaction rate of each substance in a steady state were obtained following the procedure of the first glucose uptake rate estimating process. Tables 2 to 4 show initial values used in the first glucose uptake rate estimating process, and variables (variables of the concentration, the reaction rate, etc.) obtained in the steady state after the estimating process (hereinafter, referred to as “estimated values”). Table 2 shows initial values and estimated values of the concentrations of the substances in the insulin resistance evaluation supporting system 201, Table 3 shows initial values and estimated values of parameters (variables of items other than the concentration and the reaction rate of the substances) in the insulin signaling block 222, and Table 4 shows initial values and estimated values of the reaction rates of the substances in the insulin resistance evaluation supporting system 201.
A glucose clamp test simulation was performed by a second glucose uptake rate estimating section using, as initial values, the estimated values of the variables after the first glucose uptake rate estimating process shown in Tables 2 to 4. In this glucose clamp test simulation, estimated values in Table 1 were used as the concentrations of blood glucose, blood insulin, and blood fatty acid during the clamp (60 minutes before insulin injection), and a 300-minute process from 60 minutes before the insulin injection to 240 minutes after the injection was simulated.
As shown in
In Embodiments 1 and 2 above, the configuration is adopted in which the glucose uptake rate is estimated, the presence or absence of the insulin resistance is estimated based on the estimation result, and the insulin resistance estimation result and the estimated glucose uptake rate are displayed on an output screen, but this is not a limitation. As another embodiment, the configuration may be adopted in which a screen showing only the insulin resistance estimation result (e.g., a message indicating “it is estimated that the insulin resistance is present” or “it is estimated that the insulin resistance is not present”) is displayed. Furthermore, the configuration may be adopted in which the process in step S7 that estimates the presence or absence of the insulin resistance is not performed, and an output screen showing the estimated glucose uptake rate per unit weight is displayed when the calculated glucose uptake rate in a hyperinsulinemic state reaches a steady state. In this case, information that supports evaluation of insulin resistance (e.g., a message indicating “it is estimated that the insulin resistance is not present if the glucose uptake rate is 12 mg/kg/min or more”) may be simultaneously displayed.
Furthermore, in Embodiment 1 above, the configuration is adopted in which the input information includes the measured body weight and skeletal muscle percentage, the muscle amount is obtained from the body weight and the skeletal muscle percentage, and the glucose uptake rate per unit weight is obtained from this muscle amount, but this is not a limitation. As another embodiment, the configuration may be adopted in which the input information includes the measured muscle amount, and the glucose uptake rate per unit weight is obtained from this muscle amount.
Furthermore, in Embodiment 1 above, the configuration is adopted in which the rate of acetyl-CoA produced in the β-oxidization is adjusted due to the malonyl-CoA concentration, but this is not a limitation. As another embodiment, the configuration may be adopted in which the rate of acetyl-CoA produced in the β-oxidization is obtained without consideration of suppression due to malonyl-CoA.
Furthermore, in Embodiments 1 and 2 above, the configuration is adopted in which the input information includes the free fatty acid concentration, but this is not a limitation. As another embodiment, the configuration may be adopted in which the input information includes the triglyceride concentration instead of the free fatty acid concentration, and the free fatty acid concentration is calculated from this triglyceride concentration.
Furthermore, in Embodiment 1 above, the configuration is adopted in which the input information includes the amount of oxygen consumed and the amount of carbon dioxide produced per unit time in the skeletal muscle and the skeletal muscle percentage, but this is not a limitation. As another embodiment, the input information may include the amount of oxygen consumed and the amount of carbon dioxide produced per unit time in the whole body and the body fat percentage. In this case, the configuration is adopted in which the rate of oxygen consumed in the cell is obtained from the amount of oxygen consumed per unit time in the whole body and the body fat percentage, and the amount of carbon dioxide produced in the cell is obtained from the amount of carbon dioxide produced per unit time in the whole body and the body fat percentage.
Furthermore, in Embodiments 1 and 2 above, it is assumed that the ATP hydrolysis rate does not depend on the insulin concentration, but it is known that glycogen synthesis and sodium-potassium pump including ATP hydrolysis are activated actually depending on the insulin concentration. Accordingly, the present invention is not limited to the above-described configuration, and the ATP hydrolysis rate may change according to the insulin concentration.
Furthermore, in Embodiments 1 and 2 above, the configuration is adopted in which a value according to the GLUT4 appearance amount is calculated using the insulin amount and the fatty acyl-coenzyme A complex concentration without consideration of the diacylglycerol concentration, but this is not a limitation. It is known that the GLUT4 appearance amount is affected not only by the insulin amount and the fatty acyl-coenzyme A complex concentration but also by the diacylglycerol concentration. Thus, as another embodiment, the configuration may be adopted in which a value GLUT according to the GLUT4 appearance amount is obtained also using the diacylglycerol concentration.
Furthermore, in Embodiments 1 and 2 above, the configuration was described in which one computer 1a or 201a is caused to function as the insulin resistance evaluation supporting system 1 or 201 by causing the CPU 11a or 211a of the computer 1a or 201a to execute the insulin resistance evaluation supporting program 14a or 214a, but this is not a limitation, and the insulin resistance evaluation supporting system may be configured from a dedicated hardware circuit for executing a process substantially the same as that of the insulin resistance evaluation supporting program 14a or 214a.
Furthermore, in Embodiments 1 and 2 above, the configuration was described in which all processes in the insulin resistance evaluation supporting program are executed by a single computer 1a or 201a, but this is not a limitation, and a distributed system may be adopted in which a process similar to that of the above-described insulin resistance evaluation supporting program is executed by a plurality of apparatuses (computers) in a distributed manner.
Number | Date | Country | Kind |
---|---|---|---|
2008-171810 | Jun 2008 | JP | national |
This application is a continuation of PCT/JP2009/003002 filed on Jun. 29, 2009, which claims priority to Japanese Application No. 2008-171810 filed on Jun. 30, 2008. The entire contents of these applications are incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/JP2009/003002 | Jun 2009 | US |
Child | 12979985 | US |